explore -WSS

explore

author：leisure time 2025-10-02 23:45:05 - browse：65317

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： 10 reasons why health care startups fail

WSS

Pancreatic cancer early detection could be helped by AI

AI can’t replace a physician’s gut feeling

Humana’s losses in Medicare Advantage tank its stock

Investment in vaccine development is lagging, report finds

Key House panel plots a new health care package

The Affordable Care Act has saved billions in health care costs

hotspot

explore

explore

Jerome Adams on the need for new antivirals for Covid

White House pharmacy plagued with problems, investigation finds

Activists slam private health insurers over coverage restrictions

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Alkermes shareholders re

Custom gene therapy hints at new path for rare disease treatments

Continuity nursing helped my family in our darkest PICU moments

At Orexo, a ‘turning point’ for everything but digital health

Virginia high school admissions case could be legal follow

Humana’s losses in Medicare Advantage tank its stock

knowledge

Startup Neumora takes a novel depression drug to Phase 3

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Why you shouldn’t ask, “What country has the best health care?”

Wegovy leads to weight loss. Can it treat depression, too?

New clues to why women have higher risk of autoimmune disorders

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

hotspot

leisure time

focus

explore